Abstract | OBJECTIVE: To evaluate antibody persistence one year after three-dose primary vaccination and booster immune response during the second year of life for a fully liquid diphtheria- tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-PRP approximately T) vaccine. METHODS: Infants at 18-19 months of age were given a booster dose of either DTaP-IPV-PRP approximately T (group A) or DTaP-IPV plus PRP approximately T at separate injection sites (group B), after primary vaccination at two, four and six months of age, with the same vaccines. Antibody concentrations were measured pre- and post-booster. Reactogenicity and safety were evaluated from parent reports. RESULTS: Before the booster dose, 93.1% of group A and 95.1% of group B children still had anti-PRP antibody titers > or =0.15 microg/ml. All children had antibody levels believed to protect against tetanus, polio 1 (except one subject in group B), polio 2, polio 3, and diphtheria (except one subject in group A). At least 94% of children still had antibody concentrations > or =5 ELISA units (EU) to pertussis antigens ( pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae 2 and 3 (FIM2+3)). One month after the booster dose, all subjects achieved antibody concentrations or titers believed to be protective for PRP ( polyribose ribitol phosphate)(> or =1 microg/ml), diphtheria and tetanus (> or =0.1 IU/ml) and poliovirus types 1, 2, and 3 (> or =81/dil.), and at least 90.5% of subjects had four-fold increases in antibody concentrations to pertussis antigens following the booster. Anti-PRP geometric mean titers (GMTs) increased from 1.07 to 59.6 microg/ml and from 1.8 to 62.2 microg/ml in groups A and B, respectively. Both vaccine groups showed low reactogenicity rates. CONCLUSIONS: The fully liquid pentavalent DTaP-IPV-PRP approximately T vaccine is highly immunogenic, with good antibody persistence for each antigen approximately one year after primary vaccination and strong booster responses at 18-19 months of age. Because this combined vaccine is fully liquid, requiring no reconstitution of lyophilized PRP approximately T, the ease of use and proper administration are improved.
|
Authors | Tzou-Yien Lin, Ying-Hsiang Wang, Yhu-Chering Huang, Cheng-Hsun Chiu, Pen-Yi Lin, Chih-Jung Chen, Pascale Chavand, Esteban Ortiz |
Journal | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
(Int J Infect Dis)
Vol. 11
Issue 6
Pg. 488-95
(Nov 2007)
ISSN: 1201-9712 [Print] Canada |
PMID | 17349809
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Bacterial
- Diphtheria-Tetanus-acellular Pertussis Vaccines
- Haemophilus Vaccines
- Poliovirus Vaccine, Inactivated
|
Topics |
- Antibodies, Bacterial
(blood)
- Diphtheria-Tetanus-acellular Pertussis Vaccines
(administration & dosage, adverse effects, immunology)
- Female
- Haemophilus Vaccines
(administration & dosage, adverse effects, immunology)
- Haemophilus influenzae type b
(immunology)
- Humans
- Immunization, Secondary
- Infant
- Male
- Poliovirus Vaccine, Inactivated
(administration & dosage, adverse effects, immunology)
|